If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    News

    Quick Contact

    News articles from Aptar Pharma.

    New FDA approved combination product with Aptar Pharmas VP3 nasal spray system

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    27 Jan 22

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    17 Aug 21

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    05 Oct 20

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    17 Apr 20

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    23 Jan 20

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    25 Nov 19

    Aptar’s Nasal Unidose Device approved by US FDA

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    26 Jul 19

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    10 Jun 19

    Aptar Pharmas Freepod nasal spray device with GlaxoSmithKlines Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    16 May 19

    Join Aptar Pharmas live webinar Good medicine: Solutions for sensitive injectable formulations

    Join Aptar Pharma's live webinar "Good medicine: Solutions for sensitive injectable formulations"

    Aptar Pharma, a leading provider of innovative drug delivery systems, will host a live educational webinar presenting the benefits of high quality film coated elastomeric components and the role they play in reducing patient and regulatory risk. Taking place on October 24, 2018, at 15.00 GMT, the webinar, entitled “Good Medicine: Solutions for Sensitive Injectable Formulations” will demonstrate how high quality film coated components meet compliance expectations while maintaining safety of supply for the drug product..

    28 Sep 18

    New technologies in ophthalmic drug delivery webinar hosted by Aptar Pharma

    New technologies in ophthalmic drug delivery webinar hosted by Aptar Pharma

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced it will be hosting a live, complimentary webinar titled “Optimizing Patient Adherence and Compliance in Eye Care” on November 21 at 11AM EST. The webinar will offer expert insight from Matthias Birkhoff, Vice President Business Development at Aptar Pharma, and Dr. Degenhard Marx, Director Scientific Affairs within the Aptar Pharma Consumer Health Care Division.

    16 Nov 17

    Aptar Pharmas electronic lockout device approved by EMA

    Aptar Pharma's electronic lockout device approved by EMA

    Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG. Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl®. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuardTM.

    15 May 17

    Aptar Pharmas preservative free multi-dose ophthalmic squeeze dispenser launches in the U.S.

    Aptar Pharma's preservative free multi-dose ophthalmic squeeze dispenser launches in the U.S.

    Aptar Pharma, a global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, has partnered with a leading eye care company to develop and launch a new eye drop product, which uses Aptar Pharma's innovative preservative free multi-dose Ophthalmic Squeeze Dispenser (OSD). This is the first preservative free multi-dose eye drop featuring Aptar Pharma's OSD in the United States.

    17 May 16

    • Jo Webb
    • News Folder
    • English
    • Created 18 Aug 2015
    • Modified 18 Aug 2015
    • Hits 3913
    SR Packaging
    Webpackaging
    Conzept International